Posted by Michael Wonder on 15 Jun 2020
Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #4
15 June 2020 - The International Coalition of Medicines Regulatory Authorities convened its regular virtual meeting of regulators from around the world on 12 June 2020 to discuss high-level policy issues and regulatory approaches to ensure a coordinated response to the ongoing COVID-19 pandemic.
Meeting participants discussed the progress made on the development of International Coalition of Medicines Regulatory Authorities principles for COVID-19 clinical trials and prioritisation of compounds.
They agreed that a clear distinction between exploratory clinical trials and confirmatory studies with investigational or repurposed medicines for the treatment of COVID-19 is critical for clinical trial prioritisation.
